← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #1741 OF 1,916 MOST-CITED

Personnel capabilities

FDA cited this observation 6 times across 6 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics6
BY FISCAL YEAR
FY20241
FY20191
FY20171
FY20163

How FDA worded it — real examples

Failure to assure that personnel have a thorough understanding of the operations which they perform.

Continental Services Group, Inc. · Miami, Florida · Biologics · 2024-05-21

Failure to assure that personnel have capabilities commensurate with, the necessary training in, necessary experience in and a thorough understanding of the operations which they perform.

Veterans Affairs Long Beach Health Care System · Long Beach, California · Biologics · 2019-07-02

Failure to assure that personnel have the necessary training in and a thorough understanding of the operations which they perform.

Rush University Medical Center Blood Center · Chicago, Illinois · Biologics · 2017-02-21

Failure to assure that personnel have a thorough understanding of the operations which they perform.

American Blood Bank Corp. · Miami, Florida · Biologics · 2016-05-19

Failure to assure that personnel have a thorough understanding of the operations which they perform.

Global Life Research · Miami, Florida · Biologics · 2016-05-19

Failure to assure that personnel have the necessary training in and a thorough understanding of the operations which they perform.

Nassau Health Care Corporation d/b/a/ NuHealth · East Meadow, New York · Biologics · 2016-04-08

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementBiologics industry

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →